These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
963 related items for PubMed ID: 2601685
1. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33). Lin CW, Holladay MW, Barrett RW, Wolfram CA, Miller TR, Witte D, Kerwin JF, Wagenaar F, Nadzan AM. Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685 [Abstract] [Full Text] [Related]
2. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors. Lin CW, Shiosaki K, Miller TR, Witte DG, Bianchi BR, Wolfram CA, Kopecka H, Craig R, Wagenaar F, Nadzan AM. Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470 [Abstract] [Full Text] [Related]
3. Properties of receptors for gastrin and CCK on gastric smooth muscle cells. Menozzi D, Gardner JD, Jensen RT, Maton PN. Am J Physiol; 1989 Jul; 257(1 Pt 1):G73-9. PubMed ID: 2473654 [Abstract] [Full Text] [Related]
6. Characterization of cholecystokinin receptors and messenger RNA expression in rat pancreas: evidence for expression of cholecystokinin-A receptors but not cholecystokinin-B (gastrin) receptors. Zhou W, Povoski SP, Bell RH. J Surg Res; 1995 Mar; 58(3):281-9. PubMed ID: 7533864 [Abstract] [Full Text] [Related]
7. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702. Durieux C, Ruiz-Gayo M, Corringer PJ, Bergeron F, Ducos B, Roques BP. Mol Pharmacol; 1992 Jun; 41(6):1089-95. PubMed ID: 1614411 [Abstract] [Full Text] [Related]
8. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Behr TM, Béhé M, Angerstein C, Gratz S, Mach R, Hagemann L, Jenner N, Stiehler M, Frank-Raue K, Raue F, Becker W. Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353 [Abstract] [Full Text] [Related]
9. Benzodiazepine analogues L365,260 and L364,718 as gastrin and pancreatic CCK receptor antagonists. Huang SC, Zhang L, Chiang HC, Wank SA, Maton PN, Gardner JD, Jensen RT. Am J Physiol; 1989 Jul; 257(1 Pt 1):G169-74. PubMed ID: 2473653 [Abstract] [Full Text] [Related]
10. Novel expression of gastrin (cholecystokinin-B) receptors in azaserine-induced rat pancreatic carcinoma: receptor determination and characterization. Zhou W, Povoski SP, Longnecker DS, Bell RH. Cancer Res; 1992 Dec 15; 52(24):6905-11. PubMed ID: 1458479 [Abstract] [Full Text] [Related]
11. Stimulation of growth of azaserine-induced putative preneoplastic lesions in rat pancreas is mediated specifically by way of cholecystokinin-A receptors. Povoski SP, Zhou W, Longnecker DS, Roebuck BD, Bell RH. Cancer Res; 1993 Sep 01; 53(17):3925-9. PubMed ID: 8358719 [Abstract] [Full Text] [Related]
12. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist. Fukamizu Y, Nakajima T, Kimura K, Kanda H, Fujii M, Saito T, Kasai H. Arzneimittelforschung; 1998 Jan 01; 48(1):58-64. PubMed ID: 9522034 [Abstract] [Full Text] [Related]
13. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor. Poirot SS, Escrieut C, Dufresne M, Martinez J, Bouisson M, Vaysse N, Fourmy D. Mol Pharmacol; 1994 Apr 01; 45(4):599-607. PubMed ID: 8183238 [Abstract] [Full Text] [Related]
14. Both CCK-A and CCK-B/gastrin receptors mediate pepsinogen release in guinea pig gastric glands. Lin CW, Bianchi BR, Miller TR, Witte DG, Wolfram CA. Am J Physiol; 1992 Jun 01; 262(6 Pt 1):G1113-20. PubMed ID: 1616041 [Abstract] [Full Text] [Related]
15. Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. Chang RS, Lotti VJ, Chen TB, Kunkel KA. Mol Pharmacol; 1986 Sep 01; 30(3):212-7. PubMed ID: 3018478 [Abstract] [Full Text] [Related]
16. Characterization of SNF 9007, a novel cholecystokinin/opoid ligand in mouse ileum in vitro: evidence for involvement of cholecystokininA and cholecystokininB receptors in regulation of ion transport. Rao RK, Levenson S, Fang SN, Hruby VJ, Yamamura HI, Porreca F. J Pharmacol Exp Ther; 1994 Feb 01; 268(2):1003-9. PubMed ID: 8113956 [Abstract] [Full Text] [Related]
17. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Béhé M, Behr TM. Biopolymers; 2002 Feb 01; 66(6):399-418. PubMed ID: 12658727 [Abstract] [Full Text] [Related]
19. CCKA and CCKB receptors are expressed in small cell lung cancer lines and mediate Ca2+ mobilization and clonal growth. Sethi T, Herget T, Wu SV, Walsh JH, Rozengurt E. Cancer Res; 1993 Nov 01; 53(21):5208-13. PubMed ID: 8221657 [Abstract] [Full Text] [Related]
20. CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives. Corringer PJ, Weng JH, Ducos B, Durieux C, Boudeau P, Bohme A, Roques BP. J Med Chem; 1993 Jan 08; 36(1):166-72. PubMed ID: 8421283 [Abstract] [Full Text] [Related] Page: [Next] [New Search]